Health
globalreutersDecember 17, 20241 Mins read
Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder
globalreutersDecember 17, 20241 Mins read 
Neurocrine Biosciences’ Crenessity is now FDA approved for treating classic congenital adrenal hyperplasia (CAH), a rare and potentially fatal endocrine disorder. The approval comes with a priority review voucher, which Neurocrine could sell for around $150 million.
The post Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder appeared first on MedCity News.
Related Articles
10 Top oncologists in India for Breast Cancer Treatment
Breast cancer is a common disease in women that starts in the...
Trump, RFK Jr. and Vaccines
The Washington Post reports on a meeting between President-elect Trump, Robert F....
How to Elevate Your Content Marketing to Thought Leadership Marketing
What does it really take to stay ahead in healthcare? The answer...
THCB Gang Episode 148, Monday December 16
Joining Matthew Holt on #THCBGang on Monday December 16 at 1pm PST...
Leave a comment